For the latest updates on our ongoing response to COVID-19, please click here.

                    Pipeline

                    The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

                    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                    Pipeline

                    Viral?Diseases

                    • Biktarvy

                      HIV treatment pediatric1

                      Phase 1
                      Phase 2
                      Phase 3
                    • Capsid inhibitor (GS-6207)

                      HIV HTE2

                      Phase 1
                      Phase 2
                      Phase 3
                    • Capsid inhibitor (GS-6207)

                      HIV treatment na?ve

                      Phase 1
                      Phase 2
                      Phase 3
                    • Vesatolimod (GS-9620, TLR-7 agonist)

                      HIV cure

                      Phase 1
                      Phase 2
                      Phase 3
                    • Elipovimab (GS-9722, bNab)

                      HIV cure

                      Phase 1
                      Phase 2
                      Phase 3
                    • Selgantolimod (GS-9688, TLR-8 agonist)

                      HBV cure

                      Phase 1
                      Phase 2
                      Phase 3
                    • PD-L1 inhibitor (GS-4224)

                      HBV cure

                      Phase 1
                      Phase 2
                      Phase 3

                    1 Biktarvy HIV treatment pediatric label extension.

                    2 Registrational for heavily treatment-experienced (HTE) patients.

                    Inflammatory diseases

                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Rheumatoid arthritis

                      Phase 1
                      Phase 2
                      Phase 3
                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Ulcerative colitis

                      Phase 1
                      Phase 2
                      Phase 3
                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Crohn's disease

                      Phase 1
                      Phase 2
                      Phase 3
                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Psoriatic arthritis

                      Phase 1
                      Phase 2
                      Phase 3
                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Ankylosing spondylitis

                      Phase 1
                      Phase 2
                      Phase 3
                    • Filgotinib (GS-6034, JAK-1 inhibitor)

                      Uveitis

                      Phase 1
                      Phase 2
                      Phase 3
                    • TPL2 inhibitor (GS-4875)

                      Ulcerative colitis

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-19721

                      Osteoarthritis

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-05551

                      Inflammatory diseases

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-33121

                      Inflammatory diseases

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-39701

                      Inflammatory diseases

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-36671

                      Inflammatory diseases

                      Phase 1
                      Phase 2
                      Phase 3

                    1 Optionable partner program.

                    Fibrotic Diseases

                    • Cilofexor (GS-9674, FXR agonist)

                      PSC

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-16901

                      Idiopathic Pulmonary Fibrosis

                      Phase 1
                      Phase 2
                      Phase 3
                    • Cilofexor (FXR agonist)

                      NASH

                      Phase 1
                      Phase 2
                      Phase 3
                    • Firsocostat (ACC inhibitor)

                      NASH

                      Phase 1
                      Phase 2
                      Phase 3
                    • Selonsertib (ASK1 inhibitor) combinations

                      NASH

                      Phase 1
                      Phase 2
                      Phase 3
                    • Selonsertib (GS-4997, ASK1 inhibitor)

                      DKD

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-16901

                      Systemic sclerosis

                      Phase 1
                      Phase 2
                      Phase 3
                    • GLPG-12052

                      Idiopathic pulmonary fibrosis

                      Phase 1
                      Phase 2
                      Phase 3

                    1 Optioned parter program.

                    2 Optionable partner program.

                    Oncology

                    • KTE-X19

                      MCL

                      Phase 1
                      Phase 2
                      Phase 3
                    • Axi-cel

                      2L DLBCL

                      Phase 1
                      Phase 2
                      Phase 3
                    • Axi-cel

                      Indolent NHL

                      Phase 1
                      Phase 2
                      Phase 3
                    • Axi-cel

                      1L DLBCL

                      Phase 1
                      Phase 2
                      Phase 3
                    • Axi-cel

                      DLBCL (+rituximab or lenalidomide)

                      Phase 1
                      Phase 2
                      Phase 3
                    • KTE-X19

                      Adult ALL

                      Phase 1
                      Phase 2
                      Phase 3
                    • KTE-X19

                      Pediatric ALL

                      Phase 1
                      Phase 2
                      Phase 3
                    • KTE-X19

                      CLL

                      Phase 1
                      Phase 2
                      Phase 3
                    • Axi-cel

                      DLBCL (utomilumab)

                      Phase 1
                      Phase 2
                      Phase 3
                    • KITE-718 (MAGE A3/A6)

                      Solid tumor

                      Phase 1
                      Phase 2
                      Phase 3
                    • KITE-439 (HPV E7)

                      Solid tumor

                      Phase 1
                      Phase 2
                      Phase 3
                    • Oral PD-L1 inhibitor (GS-4224)

                      Solid tumor

                      Phase 1
                      Phase 2
                      Phase 3
                    • anti-CD73/TGF? TRAP (GS-1423)1

                      Solid tumor

                      Phase 1
                      Phase 2
                      Phase 3
                    • Bi-specific mAb (AGEN1223)2,3,4

                      Multiple

                      Phase 1
                      Phase 2
                      Phase 3
                    • Anti-CD137 mAb mAb (AGEN2373)3,4

                      Multiple

                      Phase 1
                      Phase 2
                      Phase 3

                    1 TME conditioning anti-CD73/TGF? TRAP bifunctional fusion protein (GS-1423).

                    2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

                    3 Exclusive option to license right from Agenus upon proof of concept data.

                    4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.

                    777米奇影院狠狠色